Retinal implants have gained increasing interest since it was demonstrated in acute trials that completely blind subjects do have light perception upon electrical stimulation of the inner surface ...

Pioneered by Italian ophthalmologist Benedetto Strampelli in the early 1960s, tooth-in-eye surgery is intended to minimize ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

Inside the human eye, the retina is made up of several types of cells, including the light-sensing photoreceptors that initiate the cascade of events that lead to vision.

Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...

The recommended dose is one ENCELTO implant per affected eye containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor (rhCNTF).

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

we examined the surgical outcomes of patients with glaucoma requiring a scleral buckle for retinal detachment repair who underwent concomitant scleral buckle and Baerveldt glaucoma implant (BGI ...

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

Warnings and Precautions: The SUSVIMO implant and the procedures associated ... macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME ...

Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...